Streetbeat News

Price Targets

SNDX

JP Morgan analyst Anupam Rama has maintained an Overweight rating on Syndax Pharmaceuticals (NASDAQ:SNDX) but lowered the price target from $36 to $33.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:22 pm

RAPT

JP Morgan analyst Anupam Rama has maintained an Overweight rating on RAPT Therapeutics (NASDAQ:RAPT) but lowered the price target from $39 to $32.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:17 pm

MRCY

JP Morgan analyst Seth Seifman maintains a Neutral rating on Mercury Systems (NASDAQ:MRCY) and lowers the price target from $37 to $35.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:16 pm

BHVN

JP Morgan analyst Tessa Romero maintains an Overweight rating on Biohaven (NYSE:BHVN) but has lowered the price target from $27 to $24.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:15 pm

A

JP Morgan analyst Tycho Peterson has maintained an Overweight rating on Agilent Technologies (NYSE:A) but lowered the price target from $155 to $150.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:14 pm

WEC

JP Morgan analyst Jeremy Metz maintains a Neutral rating on WEC Energy Group (NYSE:WEC) and raises the price target from $98 to $99.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:13 pm

AKAM

TD Cowen analyst Michael Elias maintains Akamai Techs (NASDAQ:AKAM) with an Outperform rating and raises the price target from $107 to $112.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 1:09 pm

MRCY

RBC Capital analyst Ken Herbert has maintained a 'Sector Perform' rating on Mercury Systems (NASDAQ:MRCY), but lowered the price target from $40 to $35.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 1:07 pm

PNR

TD Cowen analyst Joseph Giordano maintains an Outperform rating on Pentair (NYSE:PNR) and raises the price target from $65 to $75.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 1:06 pm

GBIO

JP Morgan analyst Anupam Rama maintains a Neutral rating on Generation Bio (NASDAQ:GBIO) and raises the price target from $8 to $9.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:02 pm